Skip to main content
. 2021 Jul 30;93(12):6611–6618. doi: 10.1002/jmv.27224

Table 2.

A longitudinal estimate of seroprevalence beginning May 13, 2020, through December 22, 2020, reported as the number of positive individuals over the total number tested

Phase 1 Phase 2 Phase 3
Draw sites (05/13/20 to 07/13/20) (8/13/20 to 09/25/20) (10/16/20 to 12/22/20)
Site 1 1/162 3/135 7/120
Site 2 0/50 1/37 7/39
Site 3 0/13 4/9
Site 4 0/40 1/34 4/25
Site 5 0/71 0/54 13/42
Total by phase 1/336 (0.3%) 5/260 (1.9%) 35/235 (14.8%)